Biodesix test predicts response to atezolizumab in lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers with Biodesix and Genentech presented findings on a test designed to predict response to atezolizumab (Tecentriq) in patients with non-small cell lung cancer.

The blood-based test, which uses expression data from the circulating proteome to classify patients, was found to be predictive for OS and PFS between atezolizumab and docetaxel, the companies said.

Genentech is a member of the Roche Group.

These data suggest a patient’s likelihood of benefiting from PD-L1 checkpoint inhibition can be identified through circulating proteome in blood samples. Researchers presented their findings at the Society for Immunotherapy of Cancer annual meeting in Washington, D.C.

Table of Contents